FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3109909400> ?p ?o ?g. }

• W3109909400 endingPage "481" @default.
• W3109909400 startingPage "473" @default.
• W3109909400 abstract "Background: The efficacy and safety of switching from tenofovir disoproxil fumarate-based antiretroviral therapy to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has not been widely investigated in HIV/hepatitis B virus (HBV)-coinfected Asian population. Methods: Between February and October 2018, HIV/HBV-coinfected patients who had achieved HIV viral suppression with tenofovir disoproxil fumarate-containing regimens were switched to E/C/F/TAF. Assessments of plasma HBV and HIV viral load, HBV serology, renal function, lipid profiles, and bone mineral density (BMD) were performed at weeks 24 and 48 after switch. Results: A total of 274 HIV/HBV-coinfected participants were enrolled, with 12.8% testing HBeAg-positive and 94.2% having plasma HBV DNA <20 IU/mL at baseline. At weeks 24 and 48, 92.7% and 89.8% achieved plasma HBV DNA <20 IU/mL; 4.7% and 5.1% had HBV DNA ≥20 IU/mL; and 2.6% and 5.1% had no data, respectively. At weeks 24 and 48, 95.6% and 94.2% of participants maintained HIV RNA <50 copies/mL, respectively. Compared with baseline, the median urine β2-microglobulin-to-creatinine ratio at week 48 decreased significantly from 165 to 90 μg/g (P < 0.001). The mean BMD of the spine and hip improved at week 48 (+1.77% and +1.33%, respectively). Significantly higher lipid profiles were observed after switch to E/C/F/TAF. Thirteen (4.7%) patients withdrew from the study before week 48, with 7 (2.6%) patients because of adverse effects. Conclusions: Switch to E/C/F/TAF maintained HBV and HIV viral suppression and resulted in the improvement of proteinuria and BMD of the spine and hip but increased lipid levels in HIV/HBV-coinfected patients at week 48." @default.
• W3109909400 created "2020-12-07" @default.
• W3109909400 creator A5002100400 @default.
• W3109909400 creator A5008314407 @default.
• W3109909400 creator A5009636531 @default.
• W3109909400 creator A5014753320 @default.
• W3109909400 creator A5018530414 @default.
• W3109909400 creator A5024388162 @default.
• W3109909400 creator A5032416180 @default.
• W3109909400 creator A5040417524 @default.
• W3109909400 creator A5041835555 @default.
• W3109909400 creator A5043910595 @default.
• W3109909400 creator A5051731266 @default.
• W3109909400 creator A5052266233 @default.
• W3109909400 creator A5064819119 @default.
• W3109909400 creator A5072183192 @default.
• W3109909400 creator A5084302435 @default.
• W3109909400 creator A5088359420 @default.
• W3109909400 date "2021-04-01" @default.
• W3109909400 modified "2023-10-16" @default.
• W3109909400 title "Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients" @default.
• W3109909400 cites W1690853634 @default.
• W3109909400 cites W1837343101 @default.
• W3109909400 cites W1971384013 @default.
• W3109909400 cites W1974885781 @default.
• W3109909400 cites W1977020122 @default.
• W3109909400 cites W1990722950 @default.
• W3109909400 cites W1992392338 @default.
• W3109909400 cites W2005270107 @default.
• W3109909400 cites W2015706236 @default.
• W3109909400 cites W2018605758 @default.
• W3109909400 cites W2051116409 @default.
• W3109909400 cites W2085428347 @default.
• W3109909400 cites W2107789045 @default.
• W3109909400 cites W2125211506 @default.
• W3109909400 cites W2125232731 @default.
• W3109909400 cites W2132112298 @default.
• W3109909400 cites W2136598250 @default.
• W3109909400 cites W2142153682 @default.
• W3109909400 cites W2144316550 @default.
• W3109909400 cites W2152664737 @default.
• W3109909400 cites W2156398850 @default.
• W3109909400 cites W2171150690 @default.
• W3109909400 cites W2196190612 @default.
• W3109909400 cites W2301510887 @default.
• W3109909400 cites W2331785597 @default.
• W3109909400 cites W2349813309 @default.
• W3109909400 cites W2521319515 @default.
• W3109909400 cites W2521726183 @default.
• W3109909400 cites W2523448145 @default.
• W3109909400 cites W2577777925 @default.
• W3109909400 cites W2581848544 @default.
• W3109909400 cites W2754708354 @default.
• W3109909400 cites W2782856081 @default.
• W3109909400 cites W2791839818 @default.
• W3109909400 cites W2901456774 @default.
• W3109909400 cites W2914383164 @default.
• W3109909400 cites W2928530166 @default.
• W3109909400 cites W2935959369 @default.
• W3109909400 cites W2955654823 @default.
• W3109909400 cites W2963036706 @default.
• W3109909400 cites W2970941276 @default.
• W3109909400 cites W2979917028 @default.
• W3109909400 cites W2983909317 @default.
• W3109909400 cites W2998572930 @default.
• W3109909400 cites W3003135182 @default.
• W3109909400 cites W3007144859 @default.
• W3109909400 cites W3008588374 @default.
• W3109909400 cites W4239743462 @default.
• W3109909400 doi "https://doi.org/10.1097/qai.0000000000002589" @default.
• W3109909400 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33273214" @default.
• W3109909400 hasPublicationYear "2021" @default.
• W3109909400 type Work @default.
• W3109909400 sameAs 3109909400 @default.
• W3109909400 citedByCount "11" @default.
• W3109909400 countsByYear W31099094002021 @default.
• W3109909400 countsByYear W31099094002022 @default.
• W3109909400 countsByYear W31099094002023 @default.
• W3109909400 crossrefType "journal-article" @default.
• W3109909400 hasAuthorship W3109909400A5002100400 @default.
• W3109909400 hasAuthorship W3109909400A5008314407 @default.
• W3109909400 hasAuthorship W3109909400A5009636531 @default.
• W3109909400 hasAuthorship W3109909400A5014753320 @default.
• W3109909400 hasAuthorship W3109909400A5018530414 @default.
• W3109909400 hasAuthorship W3109909400A5024388162 @default.
• W3109909400 hasAuthorship W3109909400A5032416180 @default.
• W3109909400 hasAuthorship W3109909400A5040417524 @default.
• W3109909400 hasAuthorship W3109909400A5041835555 @default.
• W3109909400 hasAuthorship W3109909400A5043910595 @default.
• W3109909400 hasAuthorship W3109909400A5051731266 @default.
• W3109909400 hasAuthorship W3109909400A5052266233 @default.
• W3109909400 hasAuthorship W3109909400A5064819119 @default.
• W3109909400 hasAuthorship W3109909400A5072183192 @default.
• W3109909400 hasAuthorship W3109909400A5084302435 @default.
• W3109909400 hasAuthorship W3109909400A5088359420 @default.
• W3109909400 hasBestOaLocation W31099094001 @default.
• W3109909400 hasConcept C126322002 @default.
• W3109909400 hasConcept C142462285 @default.

• next